The Boston Globe
03/01/2023
Chroma Medicine raises $135 million for its epigenetic editing therapies
Chroma's approach, known as epigenetic editing, could have broad applications for treating both rare and common diseases.
FIERCE BIOTECH
02/28/2023
Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform
A more cautious financing market is evidently no barrier for Chroma Medicine and its epigenetic-focused tech, with the Cambridge, Massachusetts-based biotech bagging $135 million in series B funds to build out its platform.
PR Newswire
09/20/2022
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D.